New hope has emerged for the diabetics (diabetesi) in Indonesia, especially those that have not yet undergone treatment but also indicates that improvement siginifikan.
Now, the present generation of new drugs berzat active Vildagliptin, which have claimed advantages compared to previous generations or groups.
Galvius
Picture: Galvus (vildagliptin) oral drug that is consumed once a day for people with type 2 diabetes. Vildagliptin works by increasing the number of two hormones inkretin found in the body called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
Chairman of Indonesian People Endokrinologi (PERKENI), Dr. Pradana Soewondo Sp.PD-KEMD, stated, Vildagliptin is an oral diabetes drug that uses a new approach.
"During this, just consider the diabetes treatment insulin (a hormone reduce the rate of blood glucose) only, while glukagonnya (which increase the rate of blood glucose) has not been touched," said Soewondo in the Media Management Diabetes Education in Jakarta, Thursday (16/10).
Vildagliptin Enzyme inhibitor proteins act as a Dipeptidyl Peptidase-4 (DPP-4 DOT) that poten, selective and reversibel. In simple, this drug works by improving the function of pancreas beta cells (the cells that produce insulin) and alpha pankeras cells (which produce glukagon) and improve insulin sensitivity.
Inkretin
According to Soewondo, other than lack of insulin, diabetesi also inkretin hormone deficiency, a kind of hormone that disekresi channel intestine when food in, manage and control the functioning of blood glucose. Inkretin also play a role in improving the balance between function and insulin glukagon.
Lack inkretin caused by the presence of protein DPP-4, which split the work inkretin. Nonetheless, the lack of hormones inkretin this can disrupt the balance between glukagon and insulin.
"With the presence of Enzyme inhibitor (barrier) DPP-4, the balance will be achieved so that the function of pancreas organs will be increased," said Soewondo.
Vildagliptin, continued, also menghasikan effects farmakologik improve the function of beta cells that become damaged and the only one that works against the alpha cells. The results of clinical trials indicate, patients who received vildagliptin 50mg tablet a day, betanya cells more sensitive to glucose than not.
"In other words, Valdigliptin improve pancreas function, namely to improve the sensitivity glukagon secretion of glucose and improve insulin sensitivity secretion of glucose," he said.
Vildagliptin will be marketed PT Dexa Medica effective starting in October 2008. The medicine is actually found by Novartis, a pharmaceutical company headquartered in Switzerland, but in this drug will be marketed by Dexa Medica.
"Novartis and Dexa Medica sharing Competency to make their drugs to consumers in Indonesia. Socialization and introduction to the doctor will soon be conducted this weekend in 6 large cities, "said Head of Marketing and Sales Synergy Dexa Medica, Dorothy Mary Dharma.
